🧬 ALK-Abelló: The Danish world market leader in the allergy revolution
I'll tell you how it is: I was sitting in the garden in Denmark the other day, the first hazelnut pollen flying low like fighter jets, and while I was destroying my fourth pack of tissues in ten minutes, I had an epiphany.
I looked like a rabbit on speed - red eyes, runny nose, completely exhausted.
Then I thought to myself: "If I'm going to suffer because of these tiny nature terrorists, then I damn well at least want my depot to profit from it!" Who is making money from my misery?
Who is turning my tears into Danish kroner? The answer: $ALK B (-0,59%)
ALK-Abelló.
1. the company: More than just "pollen protection"
$ALK B (-0,59%) is not a traditional pharmaceutical company that only suppresses symptoms. ALK is the pioneer of allergy immunotherapy (AIT).
The aim is to train the immune system so that the allergy disappears permanently (hyposensitization).
The highlight: ALK has radically changed the market from laborious injection cures to SLIT tablets (sublingual) tablets. The patient takes these conveniently at home. This ensures extremely high patient loyalty over the treatment period of usually three years - a "subscription model" for health.
2. the hard facts & key figures (as at: 17.03.2026)
3. the check according to your investment formulas
I. Core quality formula (growth & margin)
- Sales growth: 15,2 % + EBIT margin: 26,2 % = Score: 41.4
- Verdict:
Outstanding (> 25). ALK is a quality machine. The scaling of tablet production is driving margins massively upwards.
II. cash flow quality formula
- Free cash flow (FCF): DKK 1,432 million
- FCF yield:
~3,1 % - Verdict: Does not currently meet my 5% hurdle. Reason: ALK is investing heavily in the US launch of neffy® and new capacities. The substance is there, but is being "fed" in order to achieve the 2028 target (8.5 bn sales).
III Dividend & exclusion filter
- The yield (0.75%) is too low for pure "hunters". But: The dividend is 100% covered by cash flow (payout ratio approx. 30%). No debt for the distribution - very clean.
4. the pipeline: Where will the future money come from?
The "Holy Grail" is neffy®. The first needle-free adrenaline nasal spray for allergic shocks. It replaces the Epi-Pen.
- Status: Already being rolled out in the USA and Europe. Initial data show: 9 out of 10 patients prefer the spray to the syringe.
- New: Tablets for peanut allergies in children are in the final phase. This is a billion-dollar market with no real competition.
5. strategy & CEO voice
CEO Peter Halling (in office since the end of 2023) has sharpened the "Allergy+" strategy.
- Quote:
"2025 was a turning point. We have proven that we can achieve double-digit growth and leverage margins to 26% at the same time." - Outlook for 2026: ALK expects sales growth of 11-15% and a margin of around 25% (despite high reinvestments).
6. opponents & market environment
- Stallergenes Greer (Switzerland): The eternal rival, but technologically far behind ALK in tablets (especially in the US).
- Dermapharm (Allergopharma): Strong in Germany, but no threat to ALK's supremacy globally.
7. opportunities & risks
- Opportunities: Climate change (longer pollen season), development of the Chinese market (partnership with GenSci).
- Risks: High valuation (P/E 38 does not forgive mistakes), regulatory hurdles for pediatric approvals in the US.
8. analyst opinion
- Consensus: "Buy" (9 out of 12 analysts).
- Price target: Average 245 DKK (approx. 15% upside). Analysts particularly praise the cash position of over DKK 800 million (net cash).
9. the "chart mystery": The supposed crash
If you look at the 5-year chart, many are shocked by a massive "crash" in March 2022.
- The resolution: This was a stock split at a ratio of 1:20.
- An investor who previously held one share for e.g. DKK 3,000 then held 20 shares at DKK 150 each. The value remained the same, but many chart tools present this as a 95% crash without adjustment. No reason to panic!
10. why the chart recently "crashed" (March 2026)
In recent weeks, the share has corrected from around DKK 237 to DKK 212. The reasons:
Ex-dividend: Today (17.03.) the dividend is deducted from the share price. This always looks like a small drop in the chart.
R&D change: Henriette Mersebach, head of research for many years, left the company in February. This is causing short-term uncertainty about the speed of the pipeline.
Profit-taking: After +50% within a year, many value investors have cashed out as the P/E ratio climbed to almost 40.
Canada delay: Approval for neffy® in Canada is taking a few months longer than expected (now expected for Q2 2026).
👃 The "red nose" ending: And now for you!
So, let's get down to brass tacks (or pollen by the grasses): Which of you also belongs to the exclusive "club of the red noses"? Who already swallows the "subscription model" from ALK or perhaps even has the new nasal spray in the cupboard because they hate needles like the devil hates holy water?
Do you know the company at all, or did you previously think ALK stood for "alcohol consumption" (which would also be a strategy for some share prices)? Let me know which of you are suffering here or who is saying: "Value is more important to me than my runny nose!"
Opinions welcome: @Tenbagger2024
@Get_Rich_or_Die_Tryin
@Derspekulant1
@Stocktective
@Simpson
@Abyss
@Multibagger
@NichtRelevant
@SAUgut777
@Klein-Anleger
@PikaPika0105
@TradingHase and all those I have forgotten
